* If you want to update the article please login/register
Purpose Ductal carcinoma in situ related to invasive carcinoma u2264 1 mm in size is classified as DCIS with microinvasion rather than as invasive breast carcinoma. In published studies, the number of patients with microinvasion accounts for 1% of all breast cancers. This meta-analysis was conducted to determine the survival differences between patients with DCIS/microinvasion and those with pure DCIS. Patients with DCIS/microinvasion and loco-regional recurrence-free survival were significantly shorter in patients with DCIS/microinvasion than those with DCIS. Both overall survival and distant metastasis-free survival in patients with DCIS/microinvasion were shorter in patients with DCIS/microinvasion than in patients with DCIS/microinvasion than in patients with DCIS/microinvasion, but the difference was not statistically significant. Conclusions Based on our meta-analysis, DCIS/microinvasion may have more invasive biological and clinical characteristics than pure DCIS, undermining the potential need for closer monitoring and consideration of adjuvant treatment options in DCIS patients with microinvasive disease.
Source link: https://doi.org/10.1007/s10549-022-06800-3
Purpose Before primary IBC, the prognosis of local invasive recurrence after prior carcinoma in situ of the breast has not been well understood, and current findings are conflicting, particularly considering the specific prognosis of this entity. Methods We designed a retrospective review using data from the specialized C|u2019Or Breast and Gynecological Cancer registry, between 1998 and 2015, to compare results between three matched groups of patients with localized IBC: patients with de novo IBC, patients with de novo IBC, and patients with LIR after a first IBC. IBC-LIR patients were among 8186 people first diagnosed with IBC during our research period, and 49 IBC-LIR patients were matched to 49 IBC, and 46 IBC-LIR patients. Most of the three groups were stage I, grade II, estrogen receptor-positive, and HER2 negative, according to At diagnosis, IBC/LIR in the three groups were mainly stage I, grade II, gender receptor-positive, and HER2 negative.
Source link: https://doi.org/10.1007/s10549-022-06807-w
Objectives: The purpose was to investigate the relationship between ductal carcinoma in situ patients'u2019 characteristics, treating facilities and DCIS treatments, as well as a pilot assessing quality-of-life indicators among DCIS patients with diverse backgrounds. DCIS patients from various backgrounds were sent with a QoL questionnaire breast cancer module 23 and qualitative assessment questions. The Mastectomy prevalence was higher in academic journals than in community websites, but the use of hormone therapy was higher in community sites. Only HT side impacts negatively on QoL rankings and decision-making process between races, age, NDI, healthcare providers, and treatment facilities, with no significant difference between HT and treatment locations. Conclusion By implementing clinical pathways and a system-wide peer review, our integrated health network did not display persistently noted differences arising from socially determined health for DCIS treatments. In addition, we established the possibility of collecting QoL for DCIS women with diverse ethnic origins and various socioeconomic statuses.
Source link: https://doi.org/10.1007/s10549-022-06831-w
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions